For instance, EVs’ release results in increased tumor invasiveness by transferring tumor promoters such as mutant KRAS, Epidermal Growth Factor Receptor (EGFR) and integrins to tumor cells with wild-type KRAS [108]. The gene discussed is EGFR; the disease is neoplasm.